Organisation paid for research Program year 2024 Source: CMS Open Payments

Clinical Trials Network

Neither a doctor nor a teaching hospital

Research payments

$1,411,465

71 payments

Through program year 2024, Clinical Trials Network is reported as receiving $1,411,465 in research payments, across 71 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$55,921	1
2023	Research	$437,509	35
2022	Research	$340,845	23
2021	Research	$23,506	4
2020	Research	$90,350	1
2019	Research	$463,334	7

Breakdown

Who paid Research payments · program years 2019–2024

CapsoVision, Inc. $738,287 32 payments
Biogen, Inc. $407,147 2 payments
American Regent $162,542 7 payments
Amgen Inc. $55,921 1 payment
G1 Therapeutics, Inc. $30,100 12 payments
Penumbra, Inc. $17,468 17 payments

Studies the money was for Research payments · program years 2019–2024

Cln-Cvi-5794 $738,287 32 payments
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease $380,283 1 payment
1Vit15042 $106,356 2 payments
1Vit15042 $56,187 5 payments
P4 Uncontrolled Gout FORWARD II $55,921 1 payment
A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) $30,100 12 payments
A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities $26,864 1 payment
Storm-Pe $17,468 17 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.